Compare MBI & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBI | BNTC |
|---|---|---|
| Founded | 1973 | 1995 |
| Country | United States | United States |
| Employees | N/A | 24 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.7M | 396.3M |
| IPO Year | 1994 | 2020 |
| Metric | MBI | BNTC |
|---|---|---|
| Price | $4.43 | $10.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.00 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 429.9K | 118.5K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.04 | 6.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 90.48 | N/A |
| 52 Week Low | $4.44 | $9.85 |
| 52 Week High | $8.17 | $16.76 |
| Indicator | MBI | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 29.86 | 36.33 |
| Support Level | N/A | $10.04 |
| Resistance Level | $6.39 | $14.14 |
| Average True Range (ATR) | 0.13 | 0.65 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 7.69 | 9.25 |
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. The U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiaries.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.